Novamind to Introduce Novel Psychedelic Treatment Protocol in Online Workshop

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / ACCESSWIRE / November 9, 2020 / Novamind Ventures Inc. (”Novamind”), a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that it will be hosting an online event introducing Emotion-Focused Ketamine-Assisted Psychotherapy (”EF-KAP”) on November 9th, 2020, from 9:00 AM – 4:30 PM EST. EF-KAP is a treatment protocol combining emotion-focused therapy and ketamine-assisted psychotherapy, developed by Adele Lafrance, PhD and Reid Robison, MD, MBA, Chief Medical Officer of Novamind, who will host the online workshop.

“We are excited to introduce EF-KAP to our peers in the mental health community. Dr. Robison and I are passionate about advancing psychedelic-assisted therapy protocols and our research suggests that EF-KAP has the potential to help patients who have not responded to standard mental health treatments,” commented Dr. Adele Lafrance.

EF-KAP is the first psychedelic-assisted psychotherapy treatment protocol to be introduced by Novamind’s clinical research division, Cedar Clinical Research from its base in Springville, Utah. As a treatment model, with a focus on increasing patients’ overall skill and confidence with emotion processing, EF-KAP aims to provide lasting symptom relief from a range of mental health conditions, including anorexia nervosa and major depressive disorder.

This workshop will introduce participants to recent research from Cedar Clinical Research in support of EF-KAP, including the foundations of emotion science and emotion-focused interventions. Participants will learn the structure of the model (preparation sessions, dosing sessions and psychotherapeutic integration sessions). Strategies to increase supportive caregiver involvement will also be reviewed, including sample scripts and guidelines around dosing support and integration work. Finally, vignettes and videos will be presented to illustrate the preparation, ketamine dosing and adjunctive-psychotherapy sessions that make up the model.

For more information please visit

About Novamind
Novamind is building a global network of clinics, retreats and research sites to serve the regulated psychedelics industry. We provide access to safe, legal psychedelic experiences, while advancing research for psychedelic medicine. For more information visit

Contact Information

Yaron Conforti, CEO and Director
T: +1 (647) 953 9512